Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Romulus phage
- Development stage
- Preclinical
- Lead developer
- KU Leuven
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intravenous, Topical
01
Overview
Romulus phage (also known as *Staphylococcus virus Romulus* or vB_SauM_Romulus) is a lytic bacteriophage belonging to the family *Herelleviridae* (formerly *Myoviridae*) and the genus *Silviavirus*. Originally isolated from hospital sewage in Belgium by researchers at KU Leuven, Romulus phage specifically targets *Staphylococcus aureus*, including methicillin-resistant *S. aureus* (MRSA), daptomycin non-susceptible MRSA (DNS-MRSA), and vancomycin-intermediate *S. aureus* (VISA). It is being investigated for phage therapy, particularly in combination with other phages (such as Intesti13 and Sb-1) and standard-of-care antibiotics (like daptomycin and ceftaroline) to treat biofilm-mediated and multidrug-resistant *S. aureus* infections, such as prosthetic joint infections (PJI) and bovine mastitis. Additionally, a pre-adapted variant of Romulus phage (Prima HS) has been utilized under a magistral framework in Belgium to treat *S. aureus* colonization in patients with hidradenitis suppurativa (HS).
- Other names
- Staphylococcus phage RomulusStaphylococcus virus RomulusvB_SauM_Romulus
Beyond the preview
Go deeper on Romulus phage.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Romulus phage.